DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

Roche is planning to launch the device in select European countries soon. Following the receipt of the FDA letter, DexCom’s share price has been on a declining trend. However, few analysts do ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring blood glucose levels ...

The company does not expect the warning letter to materially impact its manufacturing capacity or sales, and it can continue to make and sell devices ... review of Dexcom’s 15-day sensor to ...

DexCom, Inc. (NASDAQ:DXCM) is a medical device company specializing in continuous ... Its CGM devices provide real-time glucose readings through a sensor, transmitter, and mobile app, eliminating ...

Any time we try a healthy new way of eating, it’s easy for doubt to creep in. Is it really working? Is it worth it? Does it ...

New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions that older adults would ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need ... for one two-week sensor and £300 for four. There are more than 25 million ...